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Abstract Cardiovascular disease (CVD) prevalence at a global level is predicted to increase
substantially over the next decade due to the increasing ageing population and
incidence of obesity. Hence, there is an urgent requirement to focus on modifiable
contributors to CVD risk, including a high dietary intake of saturated fatty acids
(SFA). As an important source of SFA in the UK diet, milk and dairy products are
often targeted for SFA reduction. The current paper acknowledges that milk is a
complex food and that simply focusing on the link between SFA and CVD risk
overlooks the other beneficial nutrients of dairy foods. The body of existing pro-
spective evidence exploring the impact of milk and dairy consumption on risk
factors for CVD is reviewed. The current paper highlights that high milk consump-
tion may be beneficial to cardiovascular health, while illustrating that the evidence
is less clear for cheese and butter intake. The option of manipulating the fatty acid
profile of ruminant milk is discussed as a potential dietary strategy for lowering SFA
intake at a population level. The review highlights that there is a necessity to
perform more well-controlled human intervention-based research that provides a
more holistic evaluation of fat-reduced and fat-modified dairy consumption on
CVD risk factors including vascular function, arterial stiffness, postprandial
lipaemia and markers of inflammation. Additionally, further research is required to
investigate the impact of different dairy products and the effect of the specific food
matrix on CVD development.
Keywords: arterial stiffness, blood pressure, cardiovascular disease, dairy products, milk,
saturated fatty acids
Introduction
Althoughmortality from cardiovascular disease (CVD) is
now falling in most European countries, CVD is ranked
as the leading cause of mortality in the UK and world-
wide (BHF 2010; WHO 2011; Nichols et al. 2012). It is
envisaged that the global prevalence of CVD will con-
tinue to increase and is expected to be responsible for
more than 23.6 million deaths by 2030 (Smith et al.
2012), a figure that is largely attributable to today’s
dramatic demographic changes with increasing propor-
tions of ageing and obese groups. The outcome of today’s
obesity and ageing trendsmay, if not moderated, result in
unsustainable costs to global society. Currently, CVD
costs the European Union (EU) economy approximately
€196 billion per annum in direct and indirect charges,
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with the cost per person in the UK exceeding the EU
average (Nichols et al. 2012). There is growing pressure
to reduce risk factors for CVD at a population level. An
atherogenic diet, characterised by a high intake of dietary
saturated fatty acids (SFA), is a key modifiable risk factor
for CVD. While the effects of the amount and type of
dietary fat have been examined in relation to CVD, less
focus has been placed on the role of animal-derived staple
foods such as milk and dairy products, which are signifi-
cant dietary sources of SFA.
Saturated fat consumption
In order to reduce the population health burden of
CVD, a number of strategies can be addressed; these
include increasing physical activity, improving weight
profiles and reducing tobacco and alcohol intake.
However, this paper will focus on strategies for combat-
ting the overconsumption of dietary SFA.
The adverse effect of SFA on CVD risk is well estab-
lished; this is primarily mediated via increases in serum
lipids, particularly low-density lipoprotein (LDL)-
cholesterol (Mensink et al. 2003). Current dietary rec-
ommendations include an intake of dietary SFA of less
than 10% of total energy (DH 1991; WHO 2008). The
current rolling National Diet and Nutrition Survey
(NDNS), as outlined in Table 1, highlights that this
dietary target is exceeded by the majority of men,
women and children in the UK (DH 2012).
Substitution of dietary saturated fat with
carbohydrate or unsaturated fatty acids
The question of whether replacement of dietary SFA
with carbohydrate (CHO), cis-polyunsaturated fatty
acids (cis-PUFA) or cis-monounsaturated fatty acids
(cis-MUFA) can have beneficial effects on CVD mortal-
ity and risk has received considerable attention (Astrup
et al. 2011; Hooper et al. 2012; Vafeiadou et al. 2012).
There would seem to be no clear evidence for a benefit
of substituting CHO for SFA in the prevention of CVD
(Astrup et al. 2011; Hooper et al. 2012) but there is
some recent evidence for the benefit of replacing SFA
with unsaturated fatty acids (Jakobsen et al. 2009;
Micha &Mozaffarian 2010; Hooper et al. 2012). There
is good evidence that replacing SFA with cis-PUFA will
reduce CVD mortality and risk markers, although there
is less information on the effects of replacing SFA with
cis-MUFA, mainly because few relevant randomised
controlled trials have been performed (Mozaffarian
et al. 2010). Overall, the Cochrane meta-analysis of
Hooper et al. (2012) identified that a reduction of
dietary SFA intake (where it is replaced by unsaturated
fat) and/or reduction of total dietary fat lowered the risk
of cardiovascular events by 14% [relative risk (RR)
0.86; 95% confidence interval (CI) 0.77–0.96] but had
no effect on total mortality.
The contribution of dairy products to
saturated fat intake
Milk and dairy products are one of the most significant
contributors to SFA intake in the UK diet. In the context
of this review, we are defining dairy as cows’ milk or any
food product derived from cows’ milk. However, it
should be noted that some dairy products (including
butter and cream) do not fall into the ‘milk and dairy’
section of the eatwell plate because they are predomi-
nantly viewed as significant sources of fat (FSA 2011).
Recent NDNS data (Table 2) suggest that milk and
dairy products are responsible for 22–25% of SFA con-
sumption in adults (DH 2011); however, it should be
noted that this analysis failed to take into account the
intake of composite dairy dishes (e.g. pizza and lasagne)
as well as butter consumption, the latter contributing
around 5% to daily average saturated fat intakes; thus
SFA intake from milk and dairy product consumption
may be underestimated.
Table 1 Average intake of saturated fatty acids in absolute terms and as a percentage of food/total energy, by age and gender (NDNS
2008/2009–2010/2011)
Boys/Men Girls/Women
4–18 years 19–64 years ≥65 years 4–18 years 19–64 years ≥65 years
SFA (g/day) 25.8 ± 8.6 28.8 ± 12.1 29.3 ± 10.7 22.7 ± 8.1 22.0 ± 9.8 23.2 ± 9.0
% food energy 12.9 ± 2.6 12.8 ± 3.3 14.4 ± 3.5 12.9 ± 2.7 12.6 ± 3.4 14.0 ± 3.7
% total energy 12.9 ± 2.6 12.0 ± 3.4 13.6 ± 3.4 12.9 ± 2.8 12.0 ± 3.3 13.7 ± 3.3
Source: DH (2012).
Mean ± SD. NDNS, National Diet and Nutrition Survey; SFA, saturated fatty acids.
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Effects of saturated fat in dairy products on plasma
lipids and lipoproteins
A detailed review by Huth and Park (2012) revealed
that diets higher in SFA from whole milk and butter
increase LDL-cholesterol but may also have a beneficial
impact on high-density lipoprotein (HDL)-cholesterol
concentrations, resulting in a neutral or beneficial effect
on the total cholesterol:HDL-cholesterol ratio. Fer-
mented dairy products including cheese and yogurt
appear to have a different impact on circulating levels of
plasma lipid and lipoproteins. For example, compared
to butter matched for milk fat intake, consumption of
hard cheese for a 6-week period led to significantly
lower concentrations of total cholesterol, LDL-
cholesterol and HDL-cholesterol (Hjerpsted et al.
2011). However, it should be noted that butter is not
necessarily a good comparator. There are a number of
confounding variables that negate the drawing of firm
conclusions in relation to cheese and CVD risk due to
the differential effect of individual cheese varieties that
differ in macronutrient content, degree of fermentation
and food matrix (Huth & Park 2012). Furthermore, it
highlights that the impact of dairy products on CVD
risk factors may be dependent on the specific dairy food,
even when supplying the same mass of dairy fat.
However, further long-term studies are necessary before
firmer conclusions can be drawn on the relative impact
of milk and milk-derived food consumption on plasma
lipids and lipoproteins.
The consumption of milk and milk-derived
products and cardiovascular disease
Potential benefits of milk and dairy consumption
Dairy fats are high in SFA; however, ruminant milk is a
complex food and there is much debate as to whether
nutrients within dairy foods act independently or syner-
gistically in relation to chronic disease development. The
association of SFA with CVD development may be
dependent on other nutrients/macronutrients in the
matrix of the SFA-containing food (de Oliveira Otto
et al. 2012). Milk is a significant source of a number of
essential micronutrients including calcium, potassium
and iodine. Calcium, for example, has a higher
bioavailability in milk compared with that present in
some other foods (Weaver et al. 1999). Furthermore,
mineral bioavailability is enhanced by the lack of inhibi-
tors present in milk, including phytates and oxalates,
and by the presence of lactose and certain amino acids
that may promote mineral absorption (FAO 2013).
Moreover, lipids mediate the delivery of essential fat-
soluble vitamins, including vitamins D and A, and fatty
acids associated with dairy products, namely conjugated
linoleic acids, may also have cardio-protective proper-
ties, although the data are inconsistent and require con-
firmation in further human studies (Dilzer & Park
2012). Furthermore, emerging evidence suggests that
plasma phospholipid trans-palmitoleic acid (trans 16:1
n-7), a circulating fatty acid biomarker positively corre-
Table 2 Percentage contribution of food groups to average daily total saturated fatty acid intake, by age and gender (NDNS 2008/2009–
2009/10)
Food groups (%)
Boys/Men Girls/Women
4–18 years 19–64 years ≥65 years 4–18 years 19–64 years ≥65 years
Cereals and cereal products 25 18 17 24 20 18
Milk and milk products 25 22 28 27 22 24
Eggs and egg dishes 2 3 3 2 4 4
Fat spreads 9 10 13 8 10 16
Meat and meat products 22 27 22 20 23 19
Fish and fish dishes 2 3 4 1 3 5
Vegetables and potatoes 5 7 5 6 7 6
Savoury snacks 2 1 0 2 1 0
Nuts/seeds/fruits 0 1 1 0 2 0
Sugars/preserves/confectionary 7 4 2 7 5 3
Drinks 0 1 1 0 1 0
Miscellaneous 2 3 3 2 4 3
Source: DH (2011).
NDNS, National Diet and Nutrition Survey.
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lated with self-reported intakes of dairy fat intake
(whole-fat dairy products and butter), is associated with
a more favourable metabolic profile and incident diabe-
tes rate (Micha & Mozaffarian 2010; Mozaffarian et al.
2013). However, the aforementioned findings regarding
trans 16:1 n-7 should be interpreted with caution as they
do not necessarily prove cause and effect; thus, oversim-
plifying the relationship between dairy product intake
(in terms of SFA content) and CVD risk may be mislead-
ing (Givens 2012).
Changing trends in dairy consumption
UK trends in dairy product consumption have changed
markedly over recent years; this could be partly due to
the negative connotations surrounding dairy products
and SFA content. Family Food statistics published by the
Department for Environment, Food and Rural Affairs
(Defra) over the past 20 years show a decline in total
liquid milk consumption, largely brought about by a
decrease in whole milk consumption, which now
accounts for around 20% of milk consumed in the UK
today. Butter consumption has decreased markedly
from the 1970s by about 70%, and fell around 2%
lower in the decade between 2001 and 2011, while
cheese and yogurt consumption increased by around
5% and 30%, respectively, over the same time period
(AHDB-DairyCo 2012).
Dietary patterns associated with milk and dairy
product consumption
Analysis of dietary patterns is recognised as an alternate
and complementary strategy for investigating the asso-
ciation between diet and disease risk. As dietary patterns
are more representative of overall food consumption,
they may facilitate a more valid prediction of CVD risk
compared with assessment of an individual nutrient or
food (Hu 2002). Prospective data from 88 517 middle-
aged women indicated that adherence to the Dietary
Approaches to Stop Hypertension (DASH) diet, charac-
terised by a moderate intake of low-fat dairy, legumes
and nut products, high intake of fruit, vegetables and
wholegrains, and low intake of red meat, was inversely
associated with risk of coronary heart disease (CHD)
and stroke during a 24-year follow-up period (Fung
et al. 2008). This finding was in agreement with the
Atherosclerosis Risk in Communities Study which illus-
trated that a dietary pattern rich in dairy and nut prod-
ucts, but less meat, is associated with a lower risk of
incident hypertension in middle-aged adults (Weng
et al. 2013). However, many international and national
dietary guidelines recommend the reduced intake of full-
fat dairy products as one aspect of a dietary pattern
linked to reducing risk of CHD (Erlinger & Appel
2005).
Dairy consumption and cardiovascular disease risk:
Prospective evidence
A number of studies have investigated the effect of milk
and dairy products on different CVD events. As previ-
ously mentioned, there is a lack of robust evidence on the
potential differential effects of individual dairy foods on
CVD risk as most observational studies combine dairy
products as a single food group, although milk is better
studied. A meta-analysis of prospective cohort studies
reported that, overall, high milk consumption does not
increase the RR of CHD (Elwood et al. 2008). A second
meta-analysis, which combined prospective cohort and
clinical studies, revealed that there was insufficient evi-
dence for an association between milk consumption and
CHD (RR 0.94; 95%CI 0.75–1.13) (Mente et al. 2009).
A later more extensive meta-analysis on milk and dairy
consumption and CVD events concluded that high con-
sumption of milk was related to a significant reduction in
risk of stroke development (Elwood et al. 2010). Table 3
is largely based on Elwood et al. (2010) but has been
updated by the addition of data from six recently pub-
lished studies (Bonthuis et al. 2010; Goldbohm et al.
2011; Sonestedt et al. 2011; Soedamah-Muthu et al.
2012; Avalos et al. 2013; van Aerde et al. 2013). A
recent study showed that compared with the lowest
quintile of dairy consumption, total dairy intake was
inversely related to myocardial infarction (MI) risk fol-
lowing an 11.6-year follow-up period (HR 0.77; 95%CI
0.63–0.95). Further analysis revealed that butter used on
bread was positively correlated with MI risk, while total
cheese intake had an inverse risk association (Patterson
et al. 2013). This evidence supports the hypothesis that
dairy products, excluding butter, are associated with no
detrimental effect, and in some cases a significant
reduced CVD risk.
Hypertension is one of the key risk factors for CVD
development and is influenced by gene polymorphisms,
nutrition, the environment and interactions between
these factors. Milk and milk-derived products provide
essential micronutrients (such as calcium, potassium
and iodine) and protein (whey, casein and specific
bioactive peptides), some of which have been associated
with beneficial hypotensive effects, either independently
or synergistically (Kris-Etherton et al. 2009). There are
a number of proposed mechanisms by which milk and
its components could reduce blood pressure (BP; for a
164 O. Markey et al.
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detailed review, see Fekete et al. 2013). Bioactive
peptides present in casein and whey proteins have been
observed to play a role in controlling BP by inhibiting
the action of angiotensin-I-converting enzyme, resulting
in vasodilation (FitzGerald & Meisel 2000), by modu-
lating the release of endothelin-1 by endothelial cells
(Maes et al. 2004) and acting as opioid receptor ligands
increasing nitric oxide production which mediates arte-
rial tone (Kris-Etherton et al. 2009). An important con-
sideration is the potential impact of a threshold
dependency mechanism whereby benefit is conferred in
those at low nutrient status, such as calcium, whereas in
individuals with adequate baseline status, little effect is
observed (McCarron et al. 1991; Wennersberg et al.
2009; Park & Cifelli 2013). This has important consid-
erations in respect of public health advice on dairy con-
sumption within population groups with different
nutritional status. Although the Rotterdam Study found
an inverse association between low-fat dairy intake and
hypertension risk in older adults (Engberink et al.
2009), limited evidence exists as to the potential addi-
tional benefit of low-fat dairy foods and the type of
dairy products in relation to BP reduction. Low-fat
dairy is the product of choice in most trials, yet both
low- and high-fat alternatives appear to have an overall
beneficial effect in relation to BP (Ralston et al. 2012).
Fumeron et al. (2011) reported that consumption of
either a variety of dairy products excluding cheese, or
cheese alone, and the calcium density of the diet were
associated with a lower 9-year diastolic BP after analys-
ing data from the Epidemiological Study on the Insulin
Resistance Syndrome. Moreover, data from the Caer-
philly Prospective Study illustrated that when compared
to non-milk consumers, men who consumed >586 ml/
day had a 10.4 mmHg lower systolic BP after a 22.8-
year follow-up (Livingstone et al. 2013). Unsurprisingly,
greater hypotensive effects of dairy consumption are
observed in those with hypertension or who present
with calcium sensitivity. In normotensive subjects, dairy
consumption is often related to retaining BP homeosta-
sis rather than hypotensive effects (Park & Cifelli 2013).
Elasticity of the blood vessels can be influenced by
chronic dietary patterns (Kesse-Guyot et al. 2010). Car-
diovascular events and all-cause mortality are indepen-
dently predicted by carotid-femoral pulse wave velocity
(PWV), the gold standard measurement of arterial stiff-
ness (Vlachopoulos et al. 2010; Van Bortel et al. 2012).
Further evidence from the Caerphilly Prospective Study
highlighted that, with the exception of butter consump-
tion, dairy product intake does not impact negatively on
PWV (Livingstone et al. 2013). Furthermore, augmen-
tation index, another indicator of arterial stiffness, was
1.8% lower in men with the highest quartiles of dairy
food consumption (Livingstone et al. 2013). Similarly,
cross-sectional study findings illustrated that dairy food
intake was inversely correlated with PWV (Crichton
et al. 2012a).
A low-grade systemic inflammation is recognised as a
major factor contributing to the development and pro-
gression of a number of disorders related to CVD
(Labonte et al. 2013). Cross-sectional studies that have
investigated the relationship between dairy intake and
low-grade systemic inflammation have found an inverse
association (Salas-Salvado et al. 2008; Esmaillzadeh &
Azadbakht 2010). However, a review that grouped
several studies involving overweight or obese subjects
found a degree of heterogeneity which hinders any defi-
nite conclusions (Labonte et al. 2013). Although there is
evidence supporting a beneficial association between
dairy consumption and inflammation, the mechanisms
are still unclear and studies are either underpowered or
use more than one type of dairy product as an interven-
tion, making it difficult to distinguish between dairy
products (Labonte et al. 2013).
Table 3 Summary of the relative risk for milk and dairy consumption and CVD events
Disease outcome
Number of cohort studies
(number used in analyses)
Adjusted RR (95% CI) for
milk/dairy consumption*
Significance of heterogeneity
between studies
Ischaemic heart disease 22 (17) 0.92 (0.86, 0.99) P = 0.765
All strokes 12 0.79 (0.68, 0.91) P = 0.001
Haemorrhagic stroke 5 0.75 (0.60, 0.94) P = 0.014
Subarachnoid bleed 3 0.93 (0.84, 1.02) P = 0.004
All-cause mortality 12 (9) 0.91 (0.78, 1.05) P = 0.070
Source: Adapted from Givens et al. (2014).
*Estimate of the risk of each disease in individuals with the highest consumption of milk/dairy products compared to the risk in individuals with the lowest
consumption.
CI, confidence interval; CVD, cardiovascular disease; RR, relative risk.
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Dietary strategies for lowering consumption
of saturated fat and the implication
for cardiovascular disease
Low-fat milk and dairy products
When compared with low-fat alternatives, there is no
established nutritional benefit of whole-fat dairy con-
sumption, except in young children; therefore, the intake
of low-fat milk and milk-related products may be con-
sidered an effective strategy to lower SFA intake.
However, there is currently no consensus on whether
fat-reduced dairy foods are associatedwith a reduced risk
of CVD (Benatar et al. 2013).Observational studies have
indicated that low-fat dairy consumption is an effective
strategy to promote lower BP levels (Engberink et al.
2009; Toledo et al. 2009; van Meijl & Mensink 2011),
circulating markers of inflammation (Esmaillzadeh &
Azadbakht 2010), the ratio of total cholesterol:HDL-
cholesterol (Mensink et al. 2003) and LDL-cholesterol
concentration (Kai et al. 2013), as well as aid in weight
maintenance or reduction (Abargouei et al. 2012). The
Nurses’ Health Study cohort illustrated that the associ-
ated RR of CHD varied according to consumption of
high-fat (RR 1.12; 95% CI 1.05–1.20) or low-fat dairy
consumption (RR 0.80; 95% CI 0.73–0.87) (Hu et al.
1999). On the contrary, findings from a prospective
population-based cohort of 33 636 women suggested
there were no significant differences between consump-
tion of specific low-fat and high-fat dairy products and
MI risk (Patterson et al. 2013). Furthermore, findings
from a 12-month randomised crossover trial concluded
that inclusion of reduced-fat dairy products in the diets of
overweight adults had no impact on cardio-metabolic
outcomes, including blood lipids, BP and arterial com-
pliance (Crichton et al. 2012b).However, before it can be
clearly established whether or not removal of milk fat is
beneficial to overall cardio-metabolic health, further evi-
dence fromwell-controlled human intervention studies is
required.
Altering the dairy cow diet to manipulate the fatty
acid profile of milk
As an alternative to promoting low-fat dairy product
consumption, modification of the fatty acid profile of
bovine milk offers a strategy for lowering the popul-
ation’s intake of SFA, by removing SFA from the food
chain, while preserving the beneficial contributions that
dairy products make to the protein and micronutrient
content of the human diet (Shingfield et al. 2008). Over
100 studies have explored the potential of partially
replacing milk SFA with cis-MUFA or cis-PUFA through
supplementation of the bovine diet with plant oils or
oilseeds (Givens & Shingfield 2006; Glasser et al. 2008).
Through a reduced synthesis of short- and medium-
chain SFA by the mammary gland, this feeding strategy
enhances the long-chain (>C18) unsaturated fatty acid
concentration in the milk (Doreau et al. 1999). Inclu-
sion of 49 g/kg of dry matter of rapeseed oil in the
ruminant diet for a 28-day period increased cis-MUFA
from 20 to 33 g/100 g FA, while reducing SFA from 70
to 55–60 g/day FA (Givens et al. 2009). Although a
more substantial decrease in SFA (∼20 g/100 g of FA)
has been documented, the alteration to milk FA compo-
sition was adversely linked to voluntary bovine nutrient
intake and milk yield compared to the control diet
(Givens et al. 2003). In order for modification of the
composition of ruminant-derived foods to be recognised
as a sustainable strategy for reducing SFA intake at a
population level, it is essential to find an optimal
balance between maximising the unsaturated FA profile
of the milk and minimising the impact of the supple-
mentation on animal performance (Givens 2008).
Furthermore, it should be considered that ruminal bio-
hydrogenation of PUFA results in the formation of inter-
mediates including trans 18:1 and leads to small
increases in PUFA relative to MUFA concentrations and
therefore, it might be more feasible to supplement the
bovine diet with MUFA (Shingfield et al. 2013).
In addition to the reductions in SFA and increases in
cis-MUFA, inclusion of unsaturated fatty acids into the
bovine-feeding regimen can lead to increased concentra-
tions of naturally produced ruminant trans fatty acid
(rTFA), namely linoleic acid isomers and trans MUFA,
in the milk. The intake of trans fatty acids (TFA) from
industrially hydrogenated vegetable oils is known to
have a negative impact on cardiovascular health
(Mozaffarian et al. 2006; Brouwer et al. 2010) and,
accordingly, there has been a significant reduction in the
level of ‘industrial’ TFA (iTFA) in the food chain
(Hulshof et al. 1999). Conversely, the association
between rTFA and CVD remains inconclusive (Gebauer
et al. 2011; Brouwer et al. 2013) with some studies
showing a cardio-protective effect of ruminant sources
of trans fats (Mozaffarian et al. 2006; Jakobsen et al.
2008). In an attempt to resolve the conflicting reports, a
systematic review and meta-analysis was undertaken by
Bendsen et al. (2011). They reported that the RR for
high vs. low quintiles of total TFA intake (2.8 to
approximately 10 g/day) was 1.22 (95% CI 1.08–1.38;
P = 0.002) for CHD events and 1.24 (95% CI 1.07–
1.43; P = 0.003) for fatal CHD. rTFA intake (0.5–1.9 g/
day) was not significantly associated with CHD risk (RR
0.92; 95% CI 0.76–1.11; P = 0.36) although neither
166 O. Markey et al.
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was iTFA. There was, however, a trend towards a posi-
tive association (RR 1.21; 95% CI 0.97–1.50; P = 0.09)
for iTFA intake. The authors concluded that while iTFA
may be positively related to CHD, rTFA is not, but the
limited number of studies available prevented a firm
conclusion concerning whether the source of TFA is
important. The lack of an association of rTFA with
CHD risk may be due to lower intake levels (Bendsen
et al. 2011). However, at levels currently consumed in
the UK diet, there is no evidence of risk from rTFA.
Over the past 10–15 years, the total TFA intake in the
UK diet has decreased substantially as a result of volun-
tary action by the UK food industry; this has led to a
greater proportion of the total dietary trans fats originat-
ing from rTFA (SACN 2007). However, while the pro-
portion of dietary rTFA has increased, the absolute
intake of ruminant fat is unchanged. The current dietary
intake of TFA in the UK (0.7% of food energy in adults)
(DH 2012) is below the recommended population
maximum (2% of food energy intake) (DH 1991), with
milk and milk products contributing to around 25% of
this intake (DH 2011). Consequently, TFA intake from
ruminant sources is not seen as a major cause of concern
to cardiovascular health at a population level (Tardy
et al. 2011; Brouwer et al. 2013). However, it has yet to
be determined whether increasing rTFA intake, through
manipulation of the fatty acid profile of milk and dairy
products to decrease SFA content, impacts on cardiovas-
cular health (Livingstone et al. 2012).
Impact of modified dairy products on
cardiovascular disease risk factors
A review of the current evidence suggests that consump-
tion of modified feed-reduced SFA milk and milk prod-
ucts may be beneficial to CVD risk in healthy and
hypercholesterolaemic populations when compared to
commercially available whole milk dairy products
(Livingstone et al. 2012). However, it should be noted
that there is a distinct lack of human intervention-based
research (Givens 2012; Livingstone et al. 2012) and the
studies that have been performed have relied on plasma
lipid levels as a predictor of CVD risk and on butter as the
main test food. Some selected data illustrate that, in
comparison to conventional milk, cheese, butter and ice
cream (70 g/100 g SFA, 28 g/100 g cis-MUFA), total
cholesterol and LDL-cholesterol were significantly
lowered following a 3-week period of consuming
matched fat-modified dairy products (51 g/100 g SFA,
39 g/100 g cis-MUFA) (Noakes et al. 1996). Dairy prod-
ucts are complex, nutrient-dense foods and focusing on a
single outcome measure could lead to misleading
conclusions by failing to establish the impact on other
CVD risk factors.
Evidence suggests that some of the effects of SFA on
CVD risk are mediated by impairment in endothelial
function and subsequent establishment of atherosclerosis
(Nicholls et al. 2006; Blumenthal et al. 2010; Vafeiadou
et al. 2012) and by influencing postprandial lipaemia
(Berry & Sanders 2005). Endothelial dysfunction, an
early modifiable event in the coronary atherosclerotic
process, is positively associated with increased risk of
CVD (De Caterina 2000; Schachinger et al. 2000). Flow-
mediated dilation, which measures the vasodilatory
response of the brachial artery to an increase in blood
flow-associated shear stress and carotid intima-media
thickness, can be used to non-invasively assess
endothelial function and arterial structural changes,
respectively (Anderson 2006). As previously discussed, it
is recommended that arterial stiffness, a surrogate
marker of central arterial function, should also be evalu-
ated when exploring the impact of modified dairy con-
sumption on cardiovascular risk factors (Givens 2012).
Postprandial lipaemia, characterised by elevated and
prolonged triacylglycerol concentrations in the fed state,
is influenced by the type and quantity of the meal fat
(Chong et al. 2010; Jackson& Lovegrove 2012; Jackson
et al. 2012). Postprandial lipaemia is a significant inde-
pendent risk marker of CVD that requires attention in
future modified fat studies (Nordestgaard et al. 2007).
Further research is warranted to examine the impact of
fat-modified or any total low-fat or full-fat dairy con-
sumption on holistic measures of CVD including vascu-
lar function, arterial stiffness, postprandial lipaemia and
inflammation.
This is currently being addressed at the University of
Reading in theRESET (REplacement of SaturatEd fat in
dairy on Total cholesterol) Study (ClinicalTrials.gov
NCT02089035), a 3-year Medical Research Council
funded project that is investigating the impact of reduc-
ing SFA intake by usingmodifiedmilk and dairy products
on vascular function and CVD risk biomarkers, without
limiting dairy product consumption. This will be
achieved by producingmilk and dairy products that have
a substantial proportion of the SFA replaced with cis-
MUFA. In a randomised, crossover, double-blind, con-
trolled study, it will be determined whether modified
dairy product consumption improves vascular function
and other CVD risk biomarkers relative to typical com-
mercially available products in both acute and chronic
settings. The project, which started in late 2013, will
provide unique evidence to inform public health policy
on food-based dietary recommendations for CVD risk
reduction.
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Conclusion
Much of the UK population currently exceeds the
dietary SFA recommendation of <11% of food energy
intake, with milk and dairy products as a group making
a considerable contribution to SFA intake in the average
UK diet. While it is intuitive to consider further reducing
dairy consumption as a means of decreasing SFA intake,
epidemiological data suggest that this strategy may be
counterproductive, given the array of cardio-metabolic
benefits that milk products appear to offer to human
health. Fat-reduced or fat-modified dairy product con-
sumption may offer a more feasible option for reducing
intake of SFA with minimal change to habitual eating
patterns and, hence, CVD risk at a population level.
Nevertheless, before the impact of both fat-reduced and
modified dairy consumption on CVD risk reduction can
be evaluated, it is essential to conduct more robust,
controlled human intervention-based research using
both traditional and novel assessments of cardiovascu-
lar risk. Additionally, more research is required to dif-
ferentiate between dairy food matrices.
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